To register for this event, please fill in your email address. Please check your emails and complete the registration process. If necessary, you will be asked for registration information first.
Akari (AKTX), the company’s executive leadership team, investigators, and independent scientific investors will hold a Research & Development Day April 24th. Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH) will be presented by Dr. Anita Hill. Key Opinion Leaders Dr. Robert Snelgrove and Professir Arne Skerra will be also be available for questions following their presentations.
Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria (PNH) will be presented by Dr Anita Hill, the lead investigator in the study. Dr Hill is a Consultant Haematologist and Honorary Clinical Associate Professor at Leeds Teaching Hospital, which is one of the world’s largest treatment centers for PNH patients.
The W Hotel
541 Lexington Avenue
New York, NY
Time: 7:30 AM Breakfast & Registration
Additional menu options can be found in the menu bar top right.